CERS.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

symbol		last	change	%chng	name	mcap	sector	wiki
CERS	US				Cerus Corporation

Market global news for CERS (US) Cerus Corporation

Global news - US chevrons indicate local prediction, arrows show global predictions

Today

previous days

	Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 marketscreener - 15:00 Thu 18 - CERS - link story
	Short Interest in Cerus Co. (NASDAQ:CERS) Rises By 16.0% modernreaders - 03:15 Mon 15 - CERS - link story
	Apheresis Market Worth $3.9 billion \| MarketsandMarkets™ prnewswire - 15:15 Fri 12 - CERS - link story
	Craig-Hallum Starts Cerus With Buy Rating, $5 Price Target marketscreener - 14:15 Fri 12 - CERS - link story
	12 law enforcement offi cers graduate from course on handling explosives postcourier pg - 01:15 Wed 10 - CERS - link story
	Cerus: FDA Approves 12-month Shelf Life For INTERCEPT Platelet Processing Sets rttnews - 13:30 Tue 26 - CERS - link story
	Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life marketscreener - 13:00 Tue 26 - CERS - link story
	Cerus (CERS) Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets streetinsider - 13:00 Tue 26 - CERS - link story
	Bouvel Investment Partners LLC Raises Position in Cerus Co. (NASDAQ:CERS) theenterpriseleader - 18:00 Wed 20 - CERS - link story
	Why Blood Components-Focused Cerus Stock Is Rising Tuesday biztoc - 19:45 Tue 19 - CERS - link story
	Why Blood Components-Focused Cerus Stock Is Rising Tuesday - Cerus (NASDAQ:CERS) benzinga - 19:30 Tue 19 - CERS - link story
	Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial marketscreener - 16:30 Tue 19 - CERS - link story
	Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients eagletribune - 14:45 Tue 19 - CERS - link story
	Cerus (CERS) Phase 3 Clinical Trial of INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Met its Primary Efficacy Endpoint streetinsider - 12:30 Tue 19 - CERS - link story
	William Mariner Greenman Sells 62,315 Shares of Cerus Co. (NASDAQ:CERS) Stock themarketsdaily - 16:00 Fri 15 - CERS - link story
	Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman Sells 62,315 Shares of Stock theenterpriseleader - 16:00 Fri 15 - CERS - link story